Can We Really Trust the Findings of the COVID-19 Research? Quality Assessment of Randomized Controlled Trials Published on COVID-19
===================================================================================================================================

* Athira S Joshy
* Christy Thomas
* Saphal Surendran
* Krishna Undela

## Abstract

**Objective** To evaluate the quality of randomized controlled trials (RCTs) published on Coronavirus Disease-19 (COVID-19) and to investigate the reasons behind compromising the quality, if found.

**Methods** A systematic literature search was performed in PubMed, Google Scholar, and Cochrane CENTRAL to identify the Randomized Controlled Trails published on Coronavirus Disease-19 between 1st Dec 2019 to 31st Aug 2021. Research articles met with study criteria were included in the study. Assessment of quality of randomized controlled trials was done using modified Jadad scale.

**Results** 21,259 records of randomized controlled trials were identified through database searching, out of which 90 randomized controlled trials were included in the study and, 34 (37.8%) were of high-quality, 46 (51.1%) were of moderate quality, and 10 (11.1 %) were of low-quality studies. There were 40 (44.4%), 38 (42.2%), and 12 (13.3%) randomized controlled trials published in the early, middle, and late terms with Jadad score 5.12±1.67, 5.34±1.32, and 5.68±1.50 respectively (P=0.52). When comparing the blinding status, appropriate blinding, and methods to evaluate adverse events in randomized controlled trials with modified Jadad score, a significant difference was observed (P<0.001). A significant moderate positive correlation was found between the impact factor of the journal and the modified Jadad scale score (R2= 0.48, P<0.001).

**Conclusion** Findings from our study indicate that accelerated publication of Coronavirus Disease-19 researches along with the fast-track review process has resulted in lowering study quality scores. With the emergence of stronger evidence, Coronavirus Disease-19 clinical studies with lower methodological quality should be revisited.

**Impacts on practice**

*   There have been numerous sacrifices and tragedies in the clinical response to covid-19. Revising the quality of randomized controlled trials published on COVID-19 as we enter the third wave of the pandemic and beyond, will improve the evidence-based practice of medications for clinical pharmacy services.

*   COVID-19 Patients will benefit from evidence-based pharmaceutical care through reduced drug-related problems.

Keywords
*   COVID-19
*   Randomized Controlled Trials
*   Jadad scale
*   Quality Assessment

## 1. INTRODUCTION

Coronavirus disease 2019 (COVID-19), was first reported on 31st December 2019 in Wuhan City, Hubei Province, China [1]. SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus) is the disease-causing agent of COVID-19. Concerned about the disease’s rapid spread, the World Health Organization (WHO) declared it a pandemic on March 11, 2020. As of January 27, 2022, WHO had confirmed 364,191,494 COVID-19 cases, with 5,631,457 deaths [2], and Omicron, a novel SARS-CoV-2 variation of concern, has been reported [3].

Since January 2020, the scientific community has responded enthusiastically to the COVID-19, with information being released at a breakneck pace. As of the time of writing, [ClinicalTrials.gov](http://ClinicalTrials.gov) had 7,047 trials registered while WHO’s International Clinical Trial Registry Platform has 12,508 trials related to COVID-19 [4]. Rapid progression of the COVID-19 pandemic combined with a lack of available knowledge to guide clinical decision-making is the reason for this exponential increase in the publication of research articles on COVID-19, in the past year [5]. WHO is bringing together scientists and global health professionals from all over the world to speed up research and development, as well as set new norms and standards to manage the coronavirus pandemic and to give proper care to the infected individuals. However, the reliability of the findings of these studies depends on the quality of the research.

The randomized controlled trial (RCT) is the recognized gold standard in clinical research and is thought to produce the best level of evidence for clinically assessing competing interventions, followed by clinical trials. RCT findings are used in Evidence-Based Medicine (EBM) because they are built on an objective, scientific, and systematic study design [6]. The peer-review and fast-track publication process may have inadvertent effects, leading to flawed methodology, and poor quality of findings on COVID-19 [7]. The COVID-19 pandemic’s urgency and severity pose both challenges and possibilities for practitioners interested in using EBM [8] and indeed the low quality of published RCTs are thrones in the road of EBM practice.

In a methodological review on the quality of COVID-19 research, authors evaluated the quality of observational studies (cohort and case-control studies), descriptive studies (case-series), and RCTs published in selected journals [9]. A study reported by Jung et.al. concluded that there were methodological and reporting issues in the articles published on COVID-19 in major clinical journals, that can result in compromising the utility of the research [10]. Both studies, however, failed to include research articles published in all relevant journals or to focus more on RCTs, which are the highest level of evidence in the evidence-based hierarchy. To the best of our knowledge, there are no studies conducted to date to find out the quality of RCTs research articles published on COVID-19. Hence, this study aimed to evaluate the quality of RCTs to investigate the reasons behind compromising the quality.

## 2. METHODOLOGY

This is a retrospective quality assessment study. Research articles were included in the study based on the following inclusion and exclusion criteria. Full-text articles of RCTs conducted either for the prevention, diagnosis, management, and treatment of COVID-19 and which were published in the English language from 1st December 2019 to 31st August 2021were included in the study. All the *in-vitro* or *in-vivo* studies, descriptive studies (Case series, Case reports, Ecological studies, Descriptive cross-sessional studies), observational cross-sessional studies, non-randomized controlled trials, studies unavailable in the electronic form and conference abstract, and some other studies (Study protocols, post hoc analyses, brief reports, study design & rationale, letters, and correspondence) were excluded from our study.

### 2.1. Search strategy

The electronic databases such as PubMed, Google Scholar, and Cochrane CENTRAL were searched from 1st December 2019 to 31st August 2021 MeSH (Medical Subject Headings) terms were identified and were combined using Boolean operators while searching in PubMed. The search strategy followed in PubMed for RCTs was ((“covid 19”[Supplementary Concept] OR “Coronavirus Infections”[MeSH Terms:noexp] OR “severe acute respiratory syndrome coronavirus 2”[Supplementary Concept]) AND (“randomized controlled trial”[Publication Type] OR (“controlled clinical trial”[Publication Type])). By using the same keywords, a search was also performed in Google Scholar and Cochrane Central, for identifying the articles published in journals that were not indexed in PubMed. The detailed search strategy can be found in the supplementary appendix (S1).

### 2.2. Data collection and analysis

#### 2.2.1. Study selection

The author (AJ) independently screened the titles and abstracts of the search results and will code them as either ‘retrieve’ (eligible or potentially eligible/unclear) or ‘do not retrieve’. We retrieved the full[text study reports of all potentially eligible studies. Two review authors (AJ and SS) independently assessed these for inclusion and recorded the reasons for the exclusion of ineligible studies. We resolved any disagreement through discussion or, if required, we consulted a third review author (KU).

#### 2.2.2. Data extraction and management

Research articles that met the study criteria were included in the study and data extraction was performed using Microsoft Excel. The following study characteristics were extracted from the included studies (if applicable); the title of the article, name of the journal, name of the authors, name of the corresponding author, name of the corresponding author’s institution, name of the publisher, country in which the study was conducted, type of the study design, year of publication, volume number, issue number, page number of the article and the information required for quality assessment of the articles.

### 2.3. Assessment of quality of the study

The quality of RCTs was assessed using the Modified Jadad scale (also known as the Oxford quality scoring system). Using this scale, studies were scored according to the presence of six features of RCTs, like randomization, blinding, withdrawals or dropouts, inclusion or exclusion criteria, statistical analysis, and the method used to assess the adverse events. Scale scores ranging from zero to eight [11,12] Two reviewers (AJ and SS) have independently assessed the quality of included studies using the Modified Jadad Scale (Supplementary appendix S2). Disagreements between the authors were resolved by consensus with a third reviewer (KU). Based on scores obtained from the scale, studies were categorized into high-quality (with a score of 6-8 points), moderate quality (4-5 points), or poor-quality (<4 points) out of a total score of 8.

### 2.4. Statistical analysis

The studies were divided into three terms: Early (2019 December to 2020 July), mid (2020 August to 2021 January), and late (2021 February to 2021 August). Counted data are described by a number and percentage. The scores obtained by Jadad score were compared and analyzed using one-way analysis of variance test whereas different quality article ratio was analyzed by chi-square test. In addition, the comparisons of different factors influencing the quality of the studies were analyzed using the Student t-test. SPSS v.22.0 was used for all statistical analysis and a P-value of <0.05 was considered statistically significant.

## 3. RESULTS

From a total of 21,259 studies identified through different databases (PubMed=11,763, Google Scholar=8,128, Cochrane CENTRAL=1,368), 90 RCTs met with study criteria were included in the study [13–102](Figure:1). Out of 90 RCTs, 59 (65.6%) were conducted for treatment, 21 (23.3%) were conducted for prevention, seven (7.8%) were conducted for management, three (3.3%) were conducted for the diagnosis of COVID-19 (Figure 2). A total of 55 (61.1%) RCTs included in the study were found to be open-labeled studies and only 26 (28.9%) studies were double-blinded (Figure 3).

![Figure 1:](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2022/04/16/2022.04.15.22273881/F1.medium.gif)

[Figure 1:](http://medrxiv.org/content/early/2022/04/16/2022.04.15.22273881/F1)

Figure 1: 
Study flow diagram of the review selection.

![Figure 2:](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2022/04/16/2022.04.15.22273881/F2.medium.gif)

[Figure 2:](http://medrxiv.org/content/early/2022/04/16/2022.04.15.22273881/F2)

Figure 2: 
The 90 RCTs with the reason for conducting the trial.

![Figure 3:](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2022/04/16/2022.04.15.22273881/F3.medium.gif)

[Figure 3:](http://medrxiv.org/content/early/2022/04/16/2022.04.15.22273881/F3)

Figure 3: 
The 92 RCTs with the type of blinding.

Out of 90 RCTs, 34 (37.8%) were of high-quality, 46 (51.1%) were of moderate quality, and 10 (11.1 %) were of low-quality studies (Table 1). According to the Jadad scale, 26 RCTs (28.9%) reported blinding, whereas only 22 (24.4%) reported adequate blinding. Only 36 (40.0%) of the 90 RCTs were reported with methodologies to assess adverse events (Table 2).

View this table:
[Table 1:](http://medrxiv.org/content/early/2022/04/16/2022.04.15.22273881/T1)

Table 1: Quality of the studies

View this table:
[Table 2:](http://medrxiv.org/content/early/2022/04/16/2022.04.15.22273881/T2)

Table 2: Components of Jaded scale and number of studies

### 3.1. Qualitative variations of RCTs by the term

There were 40 (44.4%), 38 (42.2%), and 12 (13.3%) papers published in the early, middle, and late terms, respectively. The Jadad score for the early, mid, and late terms were 5.12±1.67, 5.34±1.32, and 5.68±1.50 respectively (P=0.52). The number of high-quality articles for the early, mid, and late terms is 12 (30.0), 14(36.8), and 8(66.7) respectively. There was no significant difference observed between the number of different quality studies and different publication terms (P=0.097, Table 3).

View this table:
[Table 3:](http://medrxiv.org/content/early/2022/04/16/2022.04.15.22273881/T3)

Table 3: Quality assessment of randomized controlled trials according to the publication term

### 3.2. Analysis of factors related to the quality of the articles

It was noted that there was a statistically significant difference in the mean modified jaded scale score and number of studies by blinding status in the trials (P<0.001). Similarly, in trials with and without appropriate blinding, the mean modified Jadad scale was 7.25±0.80 and 4.59±1.01, respectively, with the difference in the score is statistically significant (P<0.001). There was also a significant variation in the number of RCTs in different quality levels and appropriate blinding (P<0.001). The mean modified Jadad scale score in RCTs mentioned with and without methods to assess adverse events were 6.12±1.43 and 4.65±1.22 respectively (P<0.001; Table 4). There was a positive correlation noticed between the impact factor of the journal and the modified Jadad scale score (R2= 0.48), which was significant at the level of P<0.001.

View this table:
[Table 4:](http://medrxiv.org/content/early/2022/04/16/2022.04.15.22273881/T4)

Table 4: Factors associated with the quality of Randomized Controlled Trials

## 4. DISCUSSION

In this review of methodological quality, COVID-19 clinical research articles were found to have a methodological flaw. Our findings support those of *Quinn TJ et*.*al*., who assessed the methodological and reporting quality of COVID-19 research papers published in major clinical journals (such as the BMJ, JAMA, The Lancet, and NEJM) from February to May 2020 and concluded that methodological and reporting issues could compromise the research’s utility. However, that study only examined the quality of scientific publications published in prominent clinical journals, which was a major limitation [9]. Our findings backed with the findings of a review of methodological quality of COVID-19 research articles published in February 2021 by Jung et al, concluded that the initial corpus of peer-reviewed COVID-19 research literature was mostly composed of observational studies that were submitted to a faster peer-review process and had lower methodological quality standards than comparable studies [10].

In our study, when comparing the modified Jadad scale score and the number of high-quality studies with the early and mid-late stages of publication, the modified Jadad scale score and the percentage of high-quality studies both increased. Early in the COVID-19 pandemic, an urgent demand for scientific data to support clinical, social, and economic decisions resulted in a shorter time to publication and an explosion of COVID-19 research published in both regular peer-reviewed journals and preprint servers. Furthermore, more than 30,000 of the COVID-19 articles published in 2020 were preprints, accounting for 17 to 30 percent of all COVID-19 research publications, and one-tenth of all preprints this year were about COVID-19, according to Dimensions [103]. This suggests that the expedited publishing of COVID-19 research, along with the accelerated review procedure, may have resulted in lower study quality scores.

We also investigated the impact of blinding and appropriate blinding in the COVID-19 RCTs, as well as their effects on study quality. We observed that there was a smaller number of the research reported with blinding and appropriate blinding, which significantly lowers the study quality. Blinding is a critical methodologic component of RCTs that helps to reduce bias and enhance the validity of the results. Since COVID-19 is a pandemic and RCT findings might impact clinical decision making, if participants are not blinded, their behavior in the trial and responses to subjective outcome measures may be influenced [104].

During the first wave of COVID-19, travel bans, quarantine, and stay-at-home measures were enacted, which were the principal barriers to doing efficient COVID-19-related research during the pandemic. The greatest concern during the clinical study was the threat of transmission of the COVID-19 infection not only to the participants but also to the researchers. Because of the small number of participants, the study had drawbacks such as a lack of power. To circumvent this hurdle, telemedicine, home medication delivery, web-based randomization, and online questionnaires were used to enroll participants in the trial [5]. However, findings of our results show that these methods resulted in the inadequacy of follow-up of participants, smaller sample size, and shorter study duration of the clinical trial, which may result in compromising the quality of the studies.

One of our study’s strengths is that we included all RCTs published on the prevention, diagnosis, treatment and management of COVID-19 from December 2019 to August 2021, and we used validated and standardized scales for quality evaluation, such as the modified Jadad scale.

Our study has certain drawbacks as well. Other quality evaluation criteria, such as sample size computation, sex reporting, and ethical approval, were not examined, and these scales can only assess methodology without regard for causal language.

In conclusion, we observed that the quality of RCTs published on COVID-19 during the pandemic has compromised. According to our findings, the expedited publishing of COVID-19 research, along with the faster review procedure, has resulted in lower study quality scores. Lack of quality can ultimately result in unreliable evidence, which will affect evidence-based clinical practice. So, there should be the adaptation of more reliable and cost-effective well-designed methods for conducting clinical trials without sacrificing data quality, ethics, safety, and efficacy and this should be a lesson learned from this catastrophe. With the emergence of stronger evidence, COVID-19 clinical studies with lower methodological quality should be revisited.

## Supporting information

supplementary appendix [[supplements/273881_file03.docx]](pending:yes)

## Data Availability

All data produced in the present study are available upon reasonable request to the authors

## CONFLICT OF INTEREST

None.

## AUTHOR’S CONTRIBUTION

Conceptualization: KU, CT. Data curation: AJ, SS. Formal analysis: AJ, SS. Methodology: AJ, CT, SS, KU. Project administration: KU. Visualization – AJ, KU. Writing – original draft: AJ, CT. Writing – review & editing: AJ, CT, SS, KU.

*   Received April 15, 2022.
*   Revision received April 15, 2022.
*   Accepted April 16, 2022.


*   © 2022, Posted by Cold Spring Harbor Laboratory

This pre-print is available under a Creative Commons License (Attribution-NoDerivs 4.0 International), CC BY-ND 4.0, as described at [http://creativecommons.org/licenses/by-nd/4.0/](http://creativecommons.org/licenses/by-nd/4.0/)

## REFERENCE

1.  1.Harapan H, Itoh N, Yufika A, Winardi W, Keam S, Te H, et al. Coronavirus disease 2019 (COVID-19): A literature review. J Infect Public Health. King Saud Bin Abdulaziz University for Health Sciences; 2020;13:667–73.
    
    

2.  2.WHO Coronavirus Disease (COVID-19) Dashboard | WHO Coronavirus Disease (COVID-19) Dashboard.
    
    

3.  3.Technical Advisory Group on Virus Evolution. Update on Omicron [Internet]. World Heal. Organ. 2021. p. 1–5. Available from: [https://www.who.int/news/item/28-11-2021-update-on-omicron](https://www.who.int/news/item/28-11-2021-update-on-omicron)
    
    

4.  4.World Health Organisation. International Clinical Trials Registry Platform. Search Portal [Internet]. 2006 [cited 2021 Dec 16];1–4. Available from: [https://www.who.int/clinical-trials-registry-platform](https://www.who.int/clinical-trials-registry-platform)
    
    

5.  5.Hashem H, Abufaraj M, Tbakhi A, Sultan I. Obstacles and Considerations Related to Clinical Trial Research During the COVID-19 Pandemic. Front Med. 2020;7:598038.
    
    

6.  6.Jüni P, Altman DG, Egger M. Systematic reviews in health care: Assessing the quality of controlled clinical trials. BMJ. 2001;323:42–6.
    
    [FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiRlVMTCI7czoxMToiam91cm5hbENvZGUiO3M6MzoiYm1qIjtzOjU6InJlc2lkIjtzOjExOiIzMjMvNzMwMy80MiI7czo0OiJhdG9tIjtzOjUwOiIvbWVkcnhpdi9lYXJseS8yMDIyLzA0LzE2LzIwMjIuMDQuMTUuMjIyNzM4ODEuYXRvbSI7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9) 

7.  7.Alexander PE, Debono VB, Mammen MJ, Iorio A, Aryal K, Deng D, et al. COVID-19 coronavirus research has overall low methodological quality thus far: case in point for chloroquine/hydroxychloroquine. J Clin Epidemiol. 2020;123:120–6.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.jclinepi.2020.04.016&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F04%2F16%2F2022.04.15.22273881.atom) 

8.  8.Carley S, Horner D, Body R, Mackway-Jones K. Evidence-based medicine and COVID-19: what to believe and when to change. Emerg Med J. 2020;37:572 LP – 575.
    
    

9.  9.Quinn TJ, Burton JK, Carter B, Cooper N, Dwan K, Field R, et al. Following the science? Comparison of methodological and reporting quality of covid-19 and other research from the first wave of the pandemic. BMC Med. 2021;19:46.
    
    

10. 10.Jung RG, Di Santo P, Clifford C, Prosperi-Porta G, Skanes S, Hung A, et al. Methodological quality of COVID-19 clinical research. Nat Commun. 2021;12:943.
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F04%2F16%2F2022.04.15.22273881.atom) 

11. 11.Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. United States; 1996;17:1–12.
    
    

12. 12.Oremus M, Wolfson C, Perrault A, Demers L, Momoli F, Moride Y. Interrater reliability of the modified Jadad quality scale for systematic reviews of Alzheimer’s disease drug trials. Dement Geriatr Cogn Disord. Switzerland; 2001;12:232–6.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1159/000051263&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=11244218&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F04%2F16%2F2022.04.15.22273881.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000167558800009&link_type=ISI) 

13. 13.Agarwal A, Mukherjee A, Kumar G, Chatterjee P, Bhatnagar T, Malhotra P, et al. Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial). BMJ [Internet]. BMJ Publishing Group Ltd.; 2020;371:m3939–m3939. Available from: [https://pubmed.ncbi.nlm.nih.gov/33093056](https://pubmed.ncbi.nlm.nih.gov/33093056)
    
    

14. 14.Investigators TWC for the R-C. Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial. JAMA. 2020;324:1317–29.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1001/jama.2020.17022&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=32876697&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F04%2F16%2F2022.04.15.22273881.atom) 

15. 15.Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet (London, England). 2020;396:467–78.
    
    

16. 16.Cao Y, Wei J, Zou L, Jiang T, Wang G, Chen L, et al. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial. J Allergy Clin Immunol. 2020;146:137-146.e3.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.jaci.2020.05.019&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=32470486&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F04%2F16%2F2022.04.15.22273881.atom) 

17. 17.Liu X, Chen H, Shang Y, Zhu H, Chen G, Chen Y, et al. Efficacy of chloroquine versus lopinavir/ritonavir in mild/general COVID-19 infection: a prospective, open-label, multicenter, randomized controlled clinical study. Trials. 2020;21:622.
    
    

18. 18.Tang W, Cao Z, Han M, Wang Z, Chen J, Sun W, et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ. 2020;369:m1849.
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6MzoiYm1qIjtzOjU6InJlc2lkIjtzOjE3OiIzNjkvbWF5MTRfNS9tMTg0OSI7czo0OiJhdG9tIjtzOjUwOiIvbWVkcnhpdi9lYXJseS8yMDIyLzA0LzE2LzIwMjIuMDQuMTUuMjIyNzM4ODEuYXRvbSI7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9) 

19. 19.Zhu F-C, Guan X-H, Li Y-H, Huang J-Y, Jiang T, Hou L-H, et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet (London, England). 2020;396:479–88.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/S0140-6736(20)31605-6&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=32702299&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F04%2F16%2F2022.04.15.22273881.atom) 

20. 20.Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet (London, England). 2020;395:1569–78.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/S0140-6736(20)31022-9&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F04%2F16%2F2022.04.15.22273881.atom) 

21. 21.Deftereos SG, Giannopoulos G, Vrachatis DA, Siasos GD, Giotaki SG, Gargalianos P, et al. Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019: The GRECCO-19 Randomized Clinical Trial. JAMA Netw open. 2020;3:e2013136.
    
    

22. 22.Laack TA, Pollok F, Sandefur BJ, Mullan AF, Russi CS, Yalamuri SM. Barrier Enclosure for Endotracheal Intubation in a Simulated COVID-19 Scenario: A Crossover Study. West J Emerg Med. 2020;21:1080–3.
    
    

23. 23.Davoodi L, Abedi SM, Salehifar E, Alizadeh-Navaei R, Rouhanizadeh H, Khorasani G, et al. Febuxostat therapy in outpatients with suspected COVID-19: A clinical trial. Int J Clin Pract. 2020;74:e13600.
    
    

24. 24.Dequin P-F, Heming N, Meziani F, Plantefève G, Voiriot G, Badié J, et al. Effect of Hydrocortisone on 21-Day Mortality or Respiratory Support Among Critically Ill Patients With COVID-19: A Randomized Clinical Trial. JAMA. 2020;324:1298–306.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1001/jama.2020.16761&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=32876689&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F04%2F16%2F2022.04.15.22273881.atom) 

25. 25.Furtado RHM, Berwanger O, Fonseca HA, Corrêa TD, Ferraz LR, Lapa MG, et al. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. Lancet (London, England). 2020;396:959–67.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/S0140-6736(20)31862-6&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=32896292&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F04%2F16%2F2022.04.15.22273881.atom) 

26. 26.Spinner CD, Gottlieb RL, Criner GJ, Arribas López JR, Cattelan AM, Soriano Viladomiu A, et al. Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial. JAMA. 2020;324:1048–57.
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F04%2F16%2F2022.04.15.22273881.atom) 

27. 27.Liu K, Chen Y, Wu D, Lin R, Wang Z, Pan L. Effects of progressive muscle relaxation on anxiety and sleep quality in patients with COVID-19. Complement Ther Clin Pract. 2020;39:101132.
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F04%2F16%2F2022.04.15.22273881.atom) 

28. 28.Wei N, Huang B-C, Lu S-J, Hu J-B, Zhou X-Y, Hu C-C, et al. Efficacy of internet-based integrated intervention on depression and anxiety symptoms in patients with COVID-19. J Zhejiang Univ Sci B. 2020;21:400–4.
    
    

29. 29.Borba MGS, Val FFA, Sampaio VS, Alexandre MAA, Melo GC, Brito M, et al. Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial. JAMA Netw open. United States; 2020;3:e208857.
    
    

30. 30.Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020;382:1787–99.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1056/NEJMoa2001282&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F04%2F16%2F2022.04.15.22273881.atom) 

31. 31.Li J, Wang X, Huang X, Chen F, Zhang X, Liu Y, et al. Application of CareDose 4D combined with Karl 3D technology in the low dose computed tomography for the follow-up of COVID-19. BMC Med Imaging. 2020;20:56.
    
    

32. 32.Davoudi-Monfared E, Rahmani H, Khalili H, Hajiabdolbaghi M, Salehi M, Abbasian L, et al. A Randomized Clinical Trial of the Efficacy and Safety of Interferon β-1a in Treatment of Severe COVID-19. Antimicrob Agents Chemother. 2020;64.
    
    

33. 33.Entrenas Castillo M, Entrenas Costa LM, Vaquero Barrios JM, Alcalá Díaz JF, López Miranda J, Bouillon R, et al. “Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: A pilot randomized clinical study”. J Steroid Biochem Mol Biol. 2020;203:105751.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.jsbmb.2020.105751&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F04%2F16%2F2022.04.15.22273881.atom) 

34. 34.Zhao H, Zhu Q, Zhang C, Li J, Wei M, Qin Y, et al. Tocilizumab combined with favipiravir in the treatment of COVID-19: A multicenter trial in a small sample size. Biomed Pharmacother. 2021;133:110825.
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F04%2F16%2F2022.04.15.22273881.atom) 

35. 35.Barnabas R V, Brown ER, Bershteyn A, Stankiewicz Karita HC, Johnston C, Thorpe LE, et al. Hydroxychloroquine as Postexposure Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 Infection[: A Randomized Trial. Ann Intern Med. 2021;174:344–52.
    
    

36. 36.Gharebaghi N, Nejadrahim R, Mousavi SJ, Sadat-Ebrahimi S-R, Hajizadeh R. The use of intravenous immunoglobulin gamma for the treatment of severe coronavirus disease 2019: a randomized placebo-controlled double-blind clinical trial. BMC Infect Dis. 2020;20:786.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1186/s12879-020-05507-4&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F04%2F16%2F2022.04.15.22273881.atom) 

37. 37.Ahmed S, Karim MM, Ross AG, Hossain MS, Clemens JD, Sumiya MK, et al. A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. Int J Infect Dis IJID Off Publ Int Soc Infect Dis. 2021;103:214–6.
    
    

38. 38.Simonovich VA, Burgos Pratx LD, Scibona P, Beruto M V, Vallone MG, Vázquez C, et al. A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia. N Engl J Med. 2021;384:619–29.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1056/NEJMoa2031304&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F04%2F16%2F2022.04.15.22273881.atom) 

39. 39.Sadoff J, Le Gars M, Shukarev G, Heerwegh D, Truyers C, de Groot AM, et al. Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine. N Engl J Med. 2021;384:1824–35.
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F04%2F16%2F2022.04.15.22273881.atom) 

40. 40.Zhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021;21:181–92.
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F04%2F16%2F2022.04.15.22273881.atom) 

41. 41.Bundgaard H, Bundgaard JS, Raaschou-Pedersen DET, von Buchwald C, Todsen T, Norsk JB, et al. Effectiveness of Adding a Mask Recommendation to Other Public Health Measures to Prevent SARS-CoV-2 Infection in Danish Mask Wearers[: A Randomized Controlled Trial. Ann Intern Med. 2021;174:335–43.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.7326/M20-6817&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=33205991&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F04%2F16%2F2022.04.15.22273881.atom) 

42. 42.Monk PD, Marsden RJ, Tear VJ, Brookes J, Batten TN, Mankowski M, et al. Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Respir Med. 2021;9:196–206.
    
    

43. 43.Hermine O, Mariette X, Tharaux P-L, Resche-Rigon M, Porcher R, Ravaud P. Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial. JAMA Intern Med. 2021;181:32–40.
    
    

44. 44.Salvarani C, Dolci G, Massari M, Merlo DF, Cavuto S, Savoldi L, et al. Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial. JAMA Intern Med. 2021;181:24–31.
    
    

45. 45.Ella R, Vadrevu KM, Jogdand H, Prasad S, Reddy S, Sarangi V, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial. Lancet Infect Dis. 2021;21:637–46.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/S1473-3099(20)30942-7&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=33485468&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F04%2F16%2F2022.04.15.22273881.atom) 

46. 46.Tang X, Feng Y-M, Ni J-X, Zhang J-Y, Liu L-M, Hu K, et al. Early Use of Corticosteroid May Prolong SARS-CoV-2 Shedding in Non-Intensive Care Unit Patients with COVID-19 Pneumonia: A Multicenter, Single-Blind, Randomized Control Trial. Respiration. 2021;100:116–26.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1159/000512063&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=33486496&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F04%2F16%2F2022.04.15.22273881.atom) 

47. 47.Hung IF-N, Lung K-C, Tso EY-K, Liu R, Chung TW-H, Chu M-Y, et al. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet (London, England). 2020;395:1695–704.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/S0140-6736(20)31042-4&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=32401715&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F04%2F16%2F2022.04.15.22273881.atom) 

48. 48.Seneviratne CJ, Balan P, Ko KKK, Udawatte NS, Lai D, Ng DHL, et al. Efficacy of commercial mouth-rinses on SARS-CoV-2 viral load in saliva: randomized control trial in Singapore. Infection. 2021;49:305–11.
    
    

49. 49.Barrett JR, Belij-Rammerstorfer S, Dold C, Ewer KJ, Folegatti PM, Gilbride C, et al. Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses. Nat Med. United States; 2021;27:279–88.
    
    

50. 50.de Alencar JCG, Moreira C de L, Müller AD, Chaves CE, Fukuhara MA, da Silva EA, et al. Double-blind, Randomized, Placebo-controlled Trial With N-acetylcysteine for Treatment of Severe Acute Respiratory Syndrome Caused by Coronavirus Disease 2019 (COVID-19). Clin Infect Dis an Off Publ Infect Dis Soc Am. 2021;72:e736–41.
    
    

51. 51.Kalil AC, Patterson TF, Mehta AK, Tomashek KM, Wolfe CR, Ghazaryan V, et al. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. N Engl J Med. Massachusetts Medical Society; 2020;384:795–807.
    
    

52. 52.Madhi SA, Baillie V, Cutland CL, Voysey M, Koen AL, Fairlie L, et al. Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant. N Engl J Med. 2021;384:1885–98.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1056/NEJMoa2102214&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=33725432&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F04%2F16%2F2022.04.15.22273881.atom) 

53. 53.Al Kaabi N, Zhang Y, Xia S, Yang Y, Al Qahtani MM, Abdulrazzaq N, et al. Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial. JAMA. 2021;326:35–45.
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F04%2F16%2F2022.04.15.22273881.atom) 

54. 54.Araimo F, Imperiale C, Tordiglione P, Ceccarelli G, Borrazzo C, Alessandri F, et al. Ozone as adjuvant support in the treatment of COVID-19: A preliminary report of probiozovid trial. J Med Virol. United States; 2021;93:2210–20.
    
    

55. 55.Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet (London, England). 2021;397:99–111.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/S0140-6736(20)32661-1&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F04%2F16%2F2022.04.15.22273881.atom) 

56. 56.Lopes RD, Macedo AVS, de Barros E Silva PGM, Moll-Bernardes RJ, Dos Santos TM, Mazza L, et al. Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19: A Randomized Clinical Trial. JAMA. 2021;325:254–64.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1001/jama.2020.25864&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=33464336&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F04%2F16%2F2022.04.15.22273881.atom) 

57. 57.Udwadia ZF, Singh P, Barkate H, Patil S, Rangwala S, Pendse A, et al. Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial. Int J Infect Dis IJID Off Publ Int Soc Infect Dis. 2021;103:62–71.
    
    

58. 58.Wang J-B, Wang Z-X, Jing J, Zhao P, Dong J-H, Zhou Y-F, et al. Exploring an Integrative Therapy for Treating COVID-19: A Randomized Controlled Trial. Chin J Integr Med. 2020;26:648–55.
    
    

59. 59.Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021;384:403–16.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1056/NEJMoa2035389&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F04%2F16%2F2022.04.15.22273881.atom) 

60. 60.Lou Y, Liu L, Yao H, Hu X, Su J, Xu K, et al. Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: An Exploratory Randomized, Controlled Trial. Eur J Pharm Sci Off J Eur Fed Pharm Sci. 2021;157:105631.
    
    

61. 61.Fong S, Li E, Violato E, Reid A, Gu Y. Impact of aerosol box on intubation during COVID-19: a simulation study of normal and difficult airways. Can J Anaesth. 2021;68:496–504.
    
    

62. 62.Abella BS, Jolkovsky EL, Biney BT, Uspal JE, Hyman MC, Frank I, et al. Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-exposure SARS-CoV-2 Prophylaxis Among Health Care Workers: A Randomized Clinical Trial. JAMA Intern Med. 2021;181:195–202.
    
    

63. 63.Schaller G, Nayar SK, Erotocritou M, Overton A, Stelzhammer T, Berber O. Efficacy of surgical helmet systems for protection against COVID-19: a double-blinded randomised control study. Int Orthop. 2021;45:39–42.
    
    

64. 64.Cheng L-L, Guan W-J, Duan C-Y, Zhang N-F, Lei C-L, Hu Y, et al. Effect of Recombinant Human Granulocyte Colony-Stimulating Factor for Patients With Coronavirus Disease 2019 (COVID-19) and Lymphopenia: A Randomized Clinical Trial. JAMA Intern Med. 2021;181:71–8.
    
    

65. 65.Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, et al. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2021;384:693–704.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1056/NEJMoa2021436&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F04%2F16%2F2022.04.15.22273881.atom) 

66. 66.Khamis F, Al Naabi H, Al Lawati A, Ambusaidi Z, Al Sharji M, Al Barwani U, et al. Randomized controlled open label trial on the use of favipiravir combined with inhaled interferon beta-1b in hospitalized patients with moderate to severe COVID-19 pneumonia. Int J Infect Dis IJID Off Publ Int Soc Infect Dis. 2021;102:538–43.
    
    

67. 67.Tabarsi P, Barati S, Jamaati H, Haseli S, Marjani M, Moniri A, et al. Evaluating the effects of Intravenous Immunoglobulin (IVIg) on the management of severe COVID-19 cases: A randomized controlled trial. Int Immunopharmacol. 2021;90:107205.
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F04%2F16%2F2022.04.15.22273881.atom) 

68. 68.Salama C, Han J, Yau L, Reiss WG, Kramer B, Neidhart JD, et al. Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia. N Engl J Med. 2021;384:20–30.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1056/NEJMoa2030340&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=33332779&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F04%2F16%2F2022.04.15.22273881.atom) 

69. 69.Abd-Elsalam S, Esmail ES, Khalaf M, Abdo EF, Medhat MA, Abd El Ghafar MS, et al. Hydroxychloroquine in the Treatment of COVID-19: A Multicenter Randomized Controlled Study. Am J Trop Med Hyg. 2020;103:1635–9.
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F04%2F16%2F2022.04.15.22273881.atom) 

70. 70.Walsh EE, Frenck RWJ, Falsey AR, Kitchin N, Absalon J, Gurtman A, et al. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. N Engl J Med. 2020;383:2439–50.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1056/NEJMoa2027906&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F04%2F16%2F2022.04.15.22273881.atom) 

71. 71.Shah M, Captain J, Vaidya V, Kulkarni A, Valsangkar K, Nair PMK, et al. Safety and efficacy of ozone therapy in mild to moderate COVID-19 patients: A phase 1/11 randomized control trial (SEOT study). Int Immunopharmacol. 2021;91:107301.
    
    

72. 72.Lyngbakken MN, Berdal J-E, Eskesen A, Kvale D, Olsen IC, Rueegg CS, et al. A pragmatic randomized controlled trial reports lack of efficacy of hydroxychloroquine on coronavirus disease 2019 viral kinetics. Nat Commun. 2020;11:5284.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1038/s41467-020-19056-6&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F04%2F16%2F2022.04.15.22273881.atom) 

73. 73.Kimura KS, Freeman MH, Wessinger BC, Gupta V, Sheng Q, Huang LC, et al. Interim analysis of an open-label randomized controlled trial evaluating nasal irrigations in non-hospitalized patients with coronavirus disease 2019. Int Forum Allergy Rhinol. 2020;10:1325–8.
    
    

74. 74.Valizadeh H, Abdolmohammadi-Vahid S, Danshina S, Ziya Gencer M, Ammari A, Sadeghi A, et al. Nano-curcumin therapy, a promising method in modulating inflammatory cytokines in COVID-19 patients. Int Immunopharmacol. 2020;89:107088.
    
    

75. 75.Stone JH, Frigault MJ, Serling-Boyd NJ, Fernandes AD, Harvey L, Foulkes AS, et al. Efficacy of Tocilizumab in Patients Hospitalized with Covid-19. N Engl J Med. 2020;383:2333–44.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1056/NEJMoa2028836&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F04%2F16%2F2022.04.15.22273881.atom) 

76. 76.Li T, Sun L, Zhang W, Zheng C, Jiang C, Chen M, et al. Bromhexine Hydrochloride Tablets for the Treatment of Moderate COVID-19: An Open-Label Randomized Controlled Pilot Study. Clin Transl Sci. 2020;13:1096–102.
    
    

77. 77.Rahmani H, Davoudi-Monfared E, Nourian A, Khalili H, Hajizadeh N, Jalalabadi NZ, et al. Interferon β-1b in treatment of severe COVID-19: A randomized clinical trial. Int Immunopharmacol. 2020;88:106903.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.intimp.2020.106903&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F04%2F16%2F2022.04.15.22273881.atom) 

78. 78.Xiao M, Tian J, Zhou Y, Xu X, Min X, Lv Y, et al. Efficacy of Huoxiang Zhengqi dropping pills and Lianhua Qingwen granules in treatment of COVID-19: A randomized controlled trial. Pharmacol Res. 2020;161:105126.
    
    

79. 79.Abbaspour Kasgari H, Moradi S, Shabani AM, Babamahmoodi F, Davoudi Badabi AR, Davoudi L, et al. Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: a single-centre, randomized controlled trial. J Antimicrob Chemother. 2020;75:3373–8.
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F04%2F16%2F2022.04.15.22273881.atom) 

80. 80.Sekhavati E, Jafari F, SeyedAlinaghi S, Jamalimoghadamsiahkali S, Sadr S, Tabarestani M, et al. Safety and effectiveness of azithromycin in patients with COVID-19: An open-label randomised trial. Int J Antimicrob Agents. 2020;56:106143.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.ijantimicag.2020.106143&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F04%2F16%2F2022.04.15.22273881.atom) 

81. 81.Sadeghi A, Ali Asgari A, Norouzi A, Kheiri Z, Anushirvani A, Montazeri M, et al. Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19): a randomized controlled trial. J Antimicrob Chemother. 2020;75:3379–85.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1093/jac/dkaa334&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=32812039&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F04%2F16%2F2022.04.15.22273881.atom) 

82. 82.Nojomi M, Yassin Z, Keyvani H, Makiani MJ, Roham M, Laali A, et al. Effect of Arbidol (Umifenovir) on COVID-19: a randomized controlled trial. BMC Infect Dis. 2020;20:954.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1186/s12879-020-05698-w&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=33317461&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F04%2F16%2F2022.04.15.22273881.atom) 

83. 83.Chen C-P, Lin Y-C, Chen T-C, Tseng T-Y, Wong H-L, Kuo C-Y, et al. A multicenter, randomized, open-label, controlled trial to evaluate the efficacy and tolerability of hydroxychloroquine and a retrospective study in adult patients with mild to moderate coronavirus disease 2019 (COVID-19). PLoS One. 2020;15:e0242763.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1371/journal.pone.0242763&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F04%2F16%2F2022.04.15.22273881.atom) 

84. 84.Lenze EJ, Mattar C, Zorumski CF, Stevens A, Schweiger J, Nicol GE, et al. Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19: A Randomized Clinical Trial. JAMA. 2020;324:2292–300.
    
    

85. 85.Keech C, Albert G, Cho I, Robertson A, Reed P, Neal S, et al. Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine. N Engl J Med. 2020;383:2320–32.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1056/nejmoa2026920&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F04%2F16%2F2022.04.15.22273881.atom) 

86. 86.Xia S, Duan K, Zhang Y, Zhao D, Zhang H, Xie Z, et al. Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials. JAMA. 2020;324:951–60.
    
    

87. 87.Liu K, Zhang W, Yang Y, Zhang J, Li Y, Chen Y. Respiratory rehabilitation in elderly patients with COVID-19: A randomized controlled study. Complement Ther Clin Pract. 2020;39:101166.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.ctcp.2020.101166&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F04%2F16%2F2022.04.15.22273881.atom) 

88. 88.Kumari P, Dembra S, Dembra P, Bhawna F, Gul A, Ali B, et al. The Role of Vitamin C as Adjuvant Therapy in COVID-19. Cureus. 2020;12:e11779.
    
    

89. 89.Zhao J, Yang X, Wang C, Song S, Cao K, Wei T, et al. Yidu-toxicity blocking lung decoction ameliorates inflammation in severe pneumonia of SARS-COV-2 patients with Yidu-toxicity blocking lung syndrome by eliminating IL-6 and TNF-a. Biomed Pharmacother. 2020;129:110436.
    
    

90. 90.Cavalcanti AB, Zampieri FG, Rosa RG, Azevedo LCP, Veiga VC, Avezum A, et al. Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19. N Engl J Med. 2020;383:2041–52.
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F04%2F16%2F2022.04.15.22273881.atom) 

91. 91.Miller J, Bruen C, Schnaus M, Zhang J, Ali S, Lind A, et al. Auxora versus standard of care for the treatment of severe or critical COVID-19 pneumonia: results from a randomized controlled trial. Crit Care. 2020;24:502.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1186/s13054-020-03220-x&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=32795330&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F04%2F16%2F2022.04.15.22273881.atom) 

92. 92.Horby P, Mafham M, Linsell L, Bell JL, Staplin N, Emberson JR, et al. Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. N Engl J Med. 2020;383:2030–40.
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F04%2F16%2F2022.04.15.22273881.atom) 

93. 93.Goldman JD, Lye DCB, Hui DS, Marks KM, Bruno R, Montejano R, et al. Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. N Engl J Med. Massachusetts Medical Society; 2020;383:1827–37.
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F04%2F16%2F2022.04.15.22273881.atom) 

94. 94.Li L, Zhang W, Hu Y, Tong X, Zheng S, Yang J, et al. Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial. JAMA. 2020;324:460–70.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1001/jama.2020.1004&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F04%2F16%2F2022.04.15.22273881.atom) 

95. 95.Zheng F, Zhou Y, Zhou Z, Ye F, Huang B, Huang Y, et al. SARS-CoV-2 clearance in COVID-19 patients with Novaferon treatment: A randomized, open-label, parallel-group trial. Int J Infect Dis IJID Off Publ Int Soc Infect Dis. 2020;99:84–91.
    
    

96. 96.Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the Treatment of Covid-19 - Final Report. N Engl J Med. 2020;383:1813–26.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1056/NEJMoa2007764&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F04%2F16%2F2022.04.15.22273881.atom) 

97. 97.Mulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature. England; 2020;586:589–93.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1038/s41586-020-2639-4&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F04%2F16%2F2022.04.15.22273881.atom) 

98. 98.Malysz M, Dabrowski M, Böttiger BW, Smereka J, Kulak K, Szarpak A, et al. Resuscitation of the patient with suspected/confirmed COVID-19 when wearing personal protective equipment: A randomized multicenter crossover simulation trial. Cardiol J. 2020;27:497–506.
    
    

99. 99.Shu L, Niu C, Li R, Huang T, Wang Y, Huang M, et al. Treatment of severe COVID-19 with human umbilical cord mesenchymal stem cells. Stem Cell Res Ther. 2020;11:361.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1186/s13287-020-01875-5&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=32811531&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F04%2F16%2F2022.04.15.22273881.atom) 

100.100.Tomazini BM, Maia IS, Cavalcanti AB, Berwanger O, Rosa RG, Veiga VC, et al. Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial. JAMA. 2020;324:1307–16.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1001/jama.2020.17021&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=32876695&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F04%2F16%2F2022.04.15.22273881.atom) 

101.101.Lemos ACB, do Espírito Santo DA, Salvetti MC, Gilio RN, Agra LB, Pazin-Filho A, et al. Therapeutic versus prophylactic anticoagulation for severe COVID-19: A randomized phase II clinical trial (HESACOVID). Thromb Res. 2020;196:359–66.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.thromres.2020.09.026&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=32977137&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F04%2F16%2F2022.04.15.22273881.atom) 

102.102.Boulware DR, Pullen MF, Bangdiwala AS, Pastick KA, Lofgren SM, Okafor EC, et al. A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. N Engl J Med. 2020;383:517–25.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1056/NEJMoa2016638&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F04%2F16%2F2022.04.15.22273881.atom) 

103.103.Else H. How a torrent of COVID science changed research publishing - in seven charts. Nature. NLM (Medline); 2020;588:553.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1038/d41586-020-03564-y&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F04%2F16%2F2022.04.15.22273881.atom) 

104.104.Karanicolas PJ, Farrokhyar F, Bhandari M. Practical tips for surgical research: blinding: who, what, when, why, how? Can J Surg. Canadian Medical Association; 2010;53:345–8.
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F04%2F16%2F2022.04.15.22273881.atom)